Product Description
Mechanisms of Action: 5-HT6 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lundbeck
Company Location: DENMARK G7 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Alzheimer Disease
Phase 2: Schizophrenia|Alzheimer Disease
Phase 1: Healthy Volunteers|Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 17475A | P1 |
Terminated |
Alzheimer Disease |
2018-02-19 |
44% |
| STAR Extension | P3 |
Completed |
Alzheimer Disease |
2017-07-06 |
|
| 2013-000001-23 | P3 |
Completed |
Alzheimer Disease |
2017-07-06 |
|
| 2012-004765-40 | P3 |
Completed |
Alzheimer Disease |
2017-01-12 |